Verrica Pharmaceuticals Inc. (VRCA) has a negative trailing P/E of -3.4, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 12.6 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -29.10%, forward earnings yield 7.96%. PEG 0.12 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 51/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -235.1 | 0.00 | -168.80 | 0.00 | - |
| 2017 | -100.8 | -0.25 | -63.87 | 0.00 | - |
| 2018 | -5.8 | -0.02 | 1.34 | 0.00 | - |
| 2019 | -14.0 | 0.72 | 6.09 | 0.00 | - |
| 2020 | -6.3 | -0.12 | 8.72 | 0.00 | - |
| 2021 | -7.1 | 0.29 | 7.60 | 20.64 | - |
| 2022 | -3.8 | 0.09 | 2.35 | 10.40 | - |
| 2023 | -5.0 | -0.05 | 16.79 | 64.77 | - |
| 2024 | -0.5 | 0.00 | -3.68 | 4.79 | - |
| 2025 | -4.9 | 0.06 | 3.58 | 2.49 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-0.10 | $0.00 | $-1.91M | - |
| 2017 | $-0.22 | $0.00 | $-4.46M | - |
| 2018 | $-1.41 | $0.00 | $-20.65M | - |
| 2019 | $-1.12 | $0.00 | $-27.95M | - |
| 2020 | $-1.82 | $0.00 | $-45.5M | - |
| 2021 | $-1.44 | $12M | $-38.9M | -324.2% |
| 2022 | $-0.81 | $9.03M | $-27.68M | -306.4% |
| 2023 | $-1.48 | $5.12M | $-67M | -1307.5% |
| 2024 | $-1.48 | $7.57M | $-76.58M | -1012.1% |
| 2025 | $-1.68 | $35.58M | $-17.89M | -50.3% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-1.45 | $-1.96 – $-0.84 | $24.83M | $16.82M – $31.65M | 2 |
| 2027 | $-0.75 | $-1.01 – $-0.43 | $45.35M | $21.2M – $66.2M | 1 |
| 2028 | $0.46 | $0.02 – $0.89 | $92.6M | $62.74M – $118.05M | 2 |
| 2029 | $1.43 | $0.83 – $1.94 | $158.2M | $107.19M – $201.68M | 1 |
| 2030 | $1.86 | $1.08 – $2.52 | $207.65M | $140.69M – $264.72M | 1 |
